Description
P23 BETRIXABAN: IMPACT ON ROUTINE AND SPECIFIC COAGULATION ASSAYS – A PRACTICAL LABORATORY GUIDE
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: P23 BETRIXABAN: IMPACT ON ROUTINE AND SPECIFIC COAGULATION ASSAYS – A PRACTICAL LABORATORY GUIDE
€3.03
Related products
-
Article: Highlights in breast cancer
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
1 year access Online Belgian Journal of Hematology (BJH)
€71.94 Add to cart
